MGManuel González-Ortiz

Manuel González-Ortiz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manuel González-Ortiz has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Esperanza Martínez-Abundis

    Departamento de Fisiología, Instituto de Terapéutica Experimental y Clínica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara

    27 shared publications
  • E Martínez-Abundis

    6 shared publications
  • E. Martínez-Abundis

    West National Medical Center Mexican Institute of Social Security

    5 shared publications
  • José A. Robles-Cervantes

    Medical Research Unit in Clinical Epidemiology, Specialties Hospital, Medical Unit of High Specialty, West National Medical Center, Mexican Institute of Social Security, Guadalajara, Mexico

    5 shared publications
  • Maria G. Ramos-Zavala

    Specialties Hospital

    5 shared publications
  • Alejandra M. Ramírez-Rodríguez

    Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico

    4 shared publications

Latest Publications

  • Anti-hyperglycemic effects of propolis or metformin in type 2 diabetes mellitus

    by Paola D. Ochoa-Morales, Manuel González-Ortiz, Esperanza Martínez-Abundis, Karina G. Pérez-Rubio, Anayeli D. J. Patiño-Laguna

    Background: The aim of this study was to evaluate the effect of propolis or metformin versus placebo on glycemic control in pharmacological treatment-naïve patients with type 2 diabetes mellitus (T2DM). Methods: A double-blind, randomized, placebo-controlled in parallel groups clinical trial was performed in 36 pharmacological treatment-naïve patients with T2DM. They received propolis (300 mg), metformin (850 mg), or placebo twice daily before breakfast and dinner for 12 weeks. At the beginning and end of the study, fasting plasma glucose (FPG), 2-h postload glucose (2-h PG) during a 75-g oral glucose tolerance test, glycated hemoglobin A1c (A1C) and a metabolic profile were measured. Areas under the curve (AUC) of glucose and insulin, total insulin secretion (insulinogenic index), the first phase of insulin secretion (Stumvoll index), and insulin sensitivity (Matsuda index) were calculated. Statistical analyses: Kruskal-Wallis, Mann-Whitney U and Wilcoxon tests. Results: The propolis and metformin groups exhibited significant reductions in FPG (p=0.009 and p=0.001, respectively), 2-h PG (p=0.034 and p=0.001, respectively) levels, AUC of insulin, Stumvoll index, and an increment in the Matsuda index. The comparison of the changes from baseline to the end showed significant differences between placebo and propolis in FPG (p=0.004) and A1C (p=0.049) levels, while between placebo and metformin were in FPG (p=0.002), 2-h PG (p=0.004) and A1C (p=0.007) levels. Conclusions: The administration of propolis and metformin compared to placebo reduced FPG and A1C levels; in addition, metformin decreased 2-h PG, AUC of glucose and insulin, high-density lipoprotein cholesterol, and increased the insulin sensitivity.


  • Open Access

    Ellagic Acid Effect on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

    by Gladys Maribel Hidalgo-Lozada, Angélica Villarruel-López, Esperanza Martínez-Abundis, Olga Vázquez-Paulino, Manuel González-Ortiz, Karina Griselda Pérez-Rubio

    Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors, usually with a common pathophysiological origin in insulin resistance and abdominal obesity. Considering the reported effects of ellagic acid (EA) on insulin resistance and abdominal obesity, the aim of this study was to evaluate the effect of EA on the components of MetS, insulin sensitivity and insulin secretion by conducting a randomized, double-blind, placebo-controlled, clinical trial with 32 volunteers diagnosed with MetS. Sixteen patients were randomly allocated, received 500 mg of EA orally twice a day for 12 weeks, and the other 16 received a placebo. Clinical and laboratory determinations were obtained at baseline and at the end of the study. After EA administration, patients reduced their waist circumference (females: 102.2 ± 4.2 to 99.5 ± 3.2 cm (p < 0.05); males: 99.8 ± 6.7 to 96.0 ± 4.7 cm (p < 0.01)), systolic blood pressure (118.1 ± 10.1 to 113.7 ± 7.8 mmHg (p < 0.01)), diastolic blood pressure (118.1 ± 10.1 to 113.7 ± 7.8 mmHg (p < 0.01)), triglycerides (2.8 ± 1.1 to 2.1 ± 0.7 mmol/L (p < 0.01)), fasting plasma glucose (6.5 ± 0.5 to 5.7 ± 0.6 mmol/L (p < 0.01)), fasting plasma insulin (p < 0.01), and insulin secretion (p < 0.05), with an increase of insulin sensitivity (p < 0.01). In male patients, high-density lipoprotein cholesterol increased (p < 0.05). In conclusion, EA improved the components of MetS, reduced hyperinsulinemia, and improved insulin sensitivity.


  • Response to Comment on Díaz-Cruz et al. Effect of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial Blood Press Monit 2020; 25:346-350

    by Cristal Díaz-Cruz, Manuel González-Ortiz, Lizet Y. Rosales-Rivera, Anayeli de J. Patiño-Laguna, Zaire G. Ramírez-Rodríguez, Karina Díaz-Cruz, Esperanza Martínez-Abundis

  • Effects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial

    by Cristal Díaz-Cruz, Manuel González-Ortiz, Lizet Y. Rosales-Rivera, Anayeli de J. Patiño-Laguna, Zaire G. Ramírez-Rodríguez, Karina Díaz-Cruz, Esperanza Martínez-Abundis

    Aim: The aim of the study was to evaluate the effect of dapagliflozin on blood pressure variability (BPV) in patients with prediabetes and prehypertension without pharmacological treatment. Methods: A double-blind, randomized, placebo-controlled clinical study was performed in 30 patients (30–60 years) diagnosed with prediabetes and prehypertension. Study subjects were divided into two groups: a 10-mg dose of dapagliflozin was administered daily before breakfast for 12 weeks in 15 patients or placebo in the remaining 15 patients. At the beginning and end of the study, clinical and metabolic evaluations were performed, and the 24-h BPV was calculated. Results: Dapagliflozin significantly decreased body weight (P = 0.010), BMI (P = 0.011), fasting plasma glucose (P = 0.002), glycated hemoglobin A1c (P = 0.004), office systolic blood pressure (SBP) (P = 0.001), office diastolic blood pressure (DBP) (P = 0.011), 24-h SBP (121 ± 8 vs. 117 ± 11 mmHg, P = 0.046), nighttime SBP (114 ± 11 vs. 108 ± 10 mmHg, P = 0.017), nocturnal mean arterial pressure (P = 0.043), and nocturnal hypertensive load (P = 0.015); and it significantly increased the percentage of the dipper circadian BP pattern (16.7 vs. 30.8%, P = 0.047). After the administration of dapagliflozin, some of the patients did not meet the diagnostic criteria for prediabetes (26.9%) or prehypertension (26.9%). Conclusions: The administration of 10 mg dapagliflozin once daily for 90 days in patients with prediabetes and prehypertension decreased BPV by reducing 24-h and nighttime SBP, and increasing the dipper circadian BP pattern.


  • Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes

    by Alejandra M. Ramírez-Rodríguez, Manuel González-Ortiz, Esperanza Martínez-Abundis

    Aim To evaluate the effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Methods A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 adults diagnosed with prediabetes and without pharmacological treatment. Patients were randomly assigned into two groups of 12 patients each to receive 10 mg of oral dapagliflozin or placebo once a day during 12 weeks. At baseline and at the end of the study, anthropometric and metabolic measurements were evaluated, including the first phase of insulin secretion, total insulin secretion, and insulin sensitivity. Results After dapagliflozin administration, there were significant decreases in body weight (80.8±16.3 vs. 77.8±14.9 kg, p=0.019), body mass index (30.3±3.5 vs. 29.2±3.1 kg/m2, p=0.023), waist circumference (100.6±13.5 vs. 96.2±11.8 cm, p=0.003), fasting glucose (5.9±0.4 vs. 5.1±0.3 mmol/L, p<0.001) and uric acid (334.3±70.8 vs. 262.9±60.7 mmol/L, p=0.032), with a tendency to increase the insulin sensitivity (1.94±0.72 vs. 2.63±1.04, p=0.064). Conclusion Dapagliflozin administration in patients with prediabetes decreased body weight, body mass index, waist circumference, fasting glucose, and uric acid, with a tendency to increase the insulin sensitivity without changes in insulin secretion.


  • Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion

    by Manuel González-Ortiz, Miriam Méndez-Del Villar, Esperanza Martínez-Abundis, Alejandra M. Ramírez-Rodríguez

    Article: Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion - Minerva Endocrinologica 2018 September;43(3):229-35 - Minerva Medica - Journals


  • Frequency of gestational diabetes mellitus and its association with risk factors in Mexico

    by Rafael M. Violante-Ortiz, Martín Marie-Tognola, José A. Cisneros-Rodríguez, Esperanza Martínez-Abundis, Miriam Méndez-Del Villar, Manuel González-Ortiz

    Article: Frequency of gestational diabetes mellitus and its association with risk factors in Mexico - Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 January-February;177(1-2):8-13 - Minerva Medica - Journals

  • Effect of Ursolic Acid on Metabolic Syndrome, Insulin Sensitivity, and Inflammation

    by Alejandra M. Ramírez-Rodríguez, Manuel González-Ortiz, Esperanza Martínez-Abundis, Natalhie Acuña Ortega

    To evaluate the effect of ursolic acid on metabolic syndrome, insulin sensitivity, and inflammation. A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients (30–60 years) with a diagnosis of metabolic syndrome without treatment. They were randomly assigned to two groups of 12 patients, each to receive orally 150 mg of ursolic acid or homologated placebo once a day for 12 weeks. Before and after the intervention, the components of metabolic syndrome, insulin sensitivity (Matsuda index), and inflammation profile (interleukin-6 and C-reactive protein) were evaluated. After ursolic acid administration, the remission of metabolic syndrome occurred in 50% of patients (P = .005) with significant differences in body weight (75.7 ± 11.5 vs. 71 ± 11 kg, P = .002), body mass index (BMI) (29.9 + 3.6 vs. 24.9 ± 1.2 kg/m2, P = .049), waist circumference (93 ± 8.9 vs. 83 + 8.6 cm, P = .008), fasting glucose (6.0 ± 0.5 vs. 4.7 ± 0.4 mmol/L, P = .002), and insulin sensitivity (3.1 ± 1.1 vs. 4.2 ± 1.2, P = .003). Ursolic acid administration leads to transient remission of metabolic syndrome, reducing body weight, BMI, waist circumference and fasting glucose, as well as increasing insulin sensitivity.


  • Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes

    by Manuel González-Ortiz, Fernando Grover-Páez, Cristal Díaz-Cruz, Anayeli de J. Patiño-Laguna, Luis D. López-Murillo, Esperanza Martínez-Abundis

    Article: Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes - Minerva Medica 2017 August;108(4):384-6 - Minerva Medica - Journals


  • Effect of tadalafil administration on insulin secretion and insulin sensitivity in obese men

    by Manuel González-Ortiz, Esperanza Martínez-Abundis, Diana M. Hernández-Corona, Alejandra M. Ramírez-Rodríguez

    Aim: To evaluate the effect of tadalafil administration on insulin secretion and insulin sensitivity in obese men without diabetes. Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in obese male patients between 30 and 50years of age. Eighteen subjects were randomly assigned to two groups of nine patients each. During a 28-day period, subjects received 5mg orally of tadalafil or placebo each night. Patients were evaluated before and after the intervention. Total insulin secretion and first phase of insulin secretion were calculated by insulinogenic index and Stumvoll index, respectively, and insulin sensitivity was calculated using the Matsuda index. Tolerability and compliance were evaluated permanently throughout the study. Results: There were no significant differences after administration of tadalafil in total insulin secretion (0.820.45 vs. 0.61 +/- 0.27, p=0.594), first phase of insulin secretion (1332 +/- 487 vs. 1602 +/- 800, p=0.779) and insulin sensitivity (4.6 +/- 1.2 vs. 4.9 +/- 2.5, p=0.779). No significant differences were shown in other measurements. Conclusion: Tadalafil administration for 28days did not modify insulin secretion or insulin sensitivity in obese men.